BridgeBio Oncology Therapeutics, Inc. (BBOT) — Cash Flow Quality Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow Quality Index of -0.04x as of December 2024. Operating cash flow of $-87.86K is below net income of $1.95 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore BBOT cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BridgeBio Oncology Therapeutics, Inc. Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore BBOT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. (2024–2024)
Year-by-year earnings quality comparison for BridgeBio Oncology Therapeutics, Inc.. For live market cap and the full company financial profile, see BridgeBio Oncology Therapeutics, Inc. (BBOT) market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | $-763.82K | $7.60 Million | — |